A phase II, multicenter, open label study of treatment escalation to ACVD (Adriamycin, Cyclophosphamide, Vinblastine and Dacarbazine) and Brentuximab-Vedotin in advanced-stage Hodgkin Lymphoma patients with a positive interim PET scan after 2 ABVD cycles (OPTIMIST study)
2022-06-27
عنوان الدراسة
A phase II, multicenter, open label study of treatment escalation to ACVD (Adriamycin, Cyclophosphamide, Vinblastine and Dacarbazine) and Brentuximab-Vedotin in advanced-stage Hodgkin Lymphoma patients with a positive interim PET scan after 2 ABVD cycles (OPTIMIST study)
داعم الدراسة
KAIMRC
دواء الدراسة
DOXORUBICIN HYDROCHLORIDE
رقم بروتوكول الدراسة
RC16/150
حالة الدراسة
Ongoing
موقع الدراسة
NGHA-R
مرحلة الدراسة
2
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。